SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- National shareholder rights firm Hagens Berman is notifying investors in Coupang, Inc. (NYSE: CPNG) that a second securities class action has been filed expanding the Class Period and seeks to represent investors who purchased Coupang securities between May 7, 2025 and December 16, 2025. The Lead Plaintiff Deadline remains February 17, 2026. The firm is investigating the propriety of Coupang's statements about its disclosure controls, cybersecurity protocols and c ...

Core Viewpoint - A securities class action lawsuit has been filed against F5, Inc. for allegedly failing to timely disclose a significant cybersecurity incident that negatively impacted its stock price and investor confidence [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Smith v. F5, Inc., seeks to represent investors who acquired F5 securities between October 28, 2024, and October 27, 2025 [1]. - The lead plaintiff deadline for the lawsuit is set for February 17, 2026 [3]. Group 2: Cybersecurity Incident - On October 15, 2025, F5 disclosed that it had experienced a major cybersecurity breach on August 9, 2025, involving unauthorized access by a nation-state actor to its systems, including its key product, F5 BIG-IP [2][6]. - Following the disclosure, F5's stock price fell by $47.82, a decrease of 13.9%, over two trading days [6]. Group 3: Financial Impact - F5 reported a significant slowdown in revenue growth, projecting only 0% to 4% growth for 2026, compared to 10% growth in 2025, attributing this deceleration to the cybersecurity incident [7]. - The day after the financial results were announced, F5's stock price dropped by $22.83, a decline of 7.8% [7]. Group 4: Investigation Focus - The investigation by Hagens Berman is centered on whether F5 appropriately informed investors about the materiality of the cybersecurity incident and adhered to SEC disclosure rules [8].

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $99 million, reflecting a 4% increase compared to Q1 2024 [20] - Adjusted EBITDA increased approximately 1% from $17.3 million to $17.5 million in Q1 2025 [20] - Adjusted EBITDA margin was 17.7%, relatively flat compared to the previous year [21] - Gross margins decreased to 64.2% from 64.6% year over year due to lower revenue from higher margin products [22] Business Line Data and Key Metrics Changes - Strength graft revenues grew 19% on a constant currency basis in Q1 2025 [8] - On X revenue increased by 11% year over year on a constant currency basis [11] - BioGlue revenues grew 9% on a constant currency basis [12] - Tissue processing revenues declined 23% year over year due to the backlog caused by a cybersecurity incident [12] Market Data and Key Metrics Changes - Latin America and Asia Pacific saw constant currency revenue growth of 268% and 14% respectively in Q1 2025 [13] - North America revenues declined by 6% compared to Q1 2024 [21] - EMEA revenues increased by 14% year over year [21] Company Strategy and Development Direction - The company is focused on ramping up On X supply and clearing the tissue processing backlog, with expectations to be fully caught up by the end of Q3 2025 [7][13] - The ongoing launch of AMDS in the U.S. is a key growth driver, with approximately 150 facilities actively seeking approvals [10][11] - The company aims to leverage positive clinical data to expand market share for On X valves, particularly among younger patients [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit revenue growth and twice that rate for EBITDA in the future [19][29] - The company raised its full-year 2025 revenue guidance to a constant currency growth range of 11% to 14% [24] - Management noted that the impact of the cybersecurity incident is being resolved, with expectations for a return to normalcy in operations [6][29] Other Important Information - The company incurred approximately $4.7 million in Q1 related to the cybersecurity incident, which is excluded from adjusted EBITDA [22] - The net leverage ratio improved to 4.0 from 4.5 year over year [24] - The company does not anticipate the need to raise additional capital to fund its operations in the foreseeable future [22] Q&A Session Summary Question: Contribution of AMDS to growth and onboarding of facilities - Management indicated that AMDS contributed to the strong growth but did not break out specific numbers. They are encouraged by the reception from the clinical community and the onboarding process is progressing well [36][38] Question: Expectations for tissue growth recovery - Management expects to return to mid-single-digit growth for tissue processing by the end of the year, with the backlog being cleared in Q2 and Q3 [40][42] Question: Cash flow expectations for the year - Management expects to be free cash flow positive for the year, despite Q1 being seasonally high in expenses [54][56] Question: Growth rates for On X and stent grafts - Management expects On X to continue double-digit growth and stent grafts to grow at a mid-teens rate, with AMDS expected to improve overall growth rates [64][66] Question: Timing for acquiring Endospan - The option to acquire Endospan will trigger upon FDA approval, expected in the second half of 2026, with a decision required within 90 days of approval [72][74] Question: Feedback on Nexus data and market opportunity - Management expressed optimism about the Nexus data and its potential market impact, noting that the mortality benefits could lead to increased adoption [80][82]